Question · asked by 1 review
HALOPERIDOL vs placebo: Leaving the study early
- Population
- patients with schizophrenia
- Intervention
- HALOPERIDOL
- Comparison
- placebo
- Outcome
- Leaving the study early
HALOPERIDOL showed no clear difference in leaving the study early compared with PLACEBO (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
HALOPERIDOL vs PLACEBO Leaving the study early · patients with schizophrenia HALOPERIDOL showed no clear difference in leaving the study early compared with PLACEBO (moderate certainty). Haloperidol versus placebo for schizophrenia (2013) · Cochrane Headline outcomes only | RR 0.54 [0.29, 1] | 8 studies · 304 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Haloperidol versus placebo for schizophrenia 2013 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- HALOPERIDOL vs OTHER ANTIPSYCHOTICS · people with long‐term aggression in psychosis · 1 review
- HALOPERIDOL vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS · patients with schizophrenia · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.